AU597262B2

AU597262B2 - Cephalosporin salts and injectable compositions

Info

Publication number: AU597262B2
Application number: AU60694/86A
Authority: AU
Inventors: Thomas W. Hudyma; Murray A. Kaplan; Robert A. Lipper
Original assignee: Bristol Myers Squibb Co
Current assignee: Bristol Myers Squibb Co
Priority date: 1985-08-05
Filing date: 1986-07-30
Publication date: 1990-05-31
Anticipated expiration: 2006-07-30
Also published as: EG18003A; LU86540A1; SU1516013A3; GB2179936B; AU6069486A; NL8601991A; OA08672A; DK371886D0; DD268395A5; PT83134B; DK162053B; CA1284994C; DD254941A5; AR243894A1; GR862055B; ES2002112A6; MY102212A; CY1614A; DK371886A; IL79608A0

Description

597262

AUJSTR'ALIA

Paten ts Act COMPLETE SPECIFICATION (ORIG(IiNA L) Class Int. Class Application Number: 6 0 69 Lodged: Complete Specification I ociged: Accepted: P'ublished: Priority Thiis docunilet conlI ns lb).

Llrnne"1ci njs ade Unider Sect Jon 49 anld is correct ft), primig, Related Art: Nani(s) or Applicant(s)'.

Address(es) of Applicant(s): APPLICANT'S REF.: Docket SY 1756 -BRISTOL-MYERS COMPANY 345 Park Avenue, New York, New York 10154 United States of America Actual Inventor(s): MURRAY A. KAPLAN, TI-IC AS W. HUtDYMA R~OBERT A. LIPPERl 0Address for Service is: 1111I1..1PS, C)RMONDE AND F ITZPATRICK Patcnt and Trade Mark Attorneys 367 Collins Street Melbourne, Australia, 300X0 Complete Specif'ication for the invention entitled: CEPIIALOSPORIN SALTS AND INJECTABLE COMPOSITIONS Trhe following statement Is a full description or thtis invention, Including the best mnethod of performing it known to BRIEF DESCRIPTION OF TI DRAWING Figure 1 is a graphical repre, .,ntation of the infra red absorption spectrum of crystalline 7-[a-(2-aminothiazol-4yl)-ct-(Z)-rethoxyiminoacetamido]-3-[ (l-methyl-l-pyrrolidinio)methyl] -3-cephem-4-carboxylate sulfate salt measured on a KBr dilution thereof.

Figure 2 is a graphical representation of the infra red absorption spectrum of the crystalline sescjuiphosphate salt of 7-[a-(2-aminothiazol-4-yl)-x-(Z)-methoxyiminoacetamido- 3 [(l-methyl-l-pyrrolidinio)-inethyl]-3-cephef4carboxylate measiired on a KBr dilution thereof.

Figure 3 is a graphical representation of the infra red absorption spectrum of the crystaLline diphosphate salt of 7-a(-mntizl4-l--Z-eh x-iioctiio--(1methyl-l-pyrrolidinio) -methyl] -3-cephem-4-carboxylate measured on a KBr dilution thereof.

GD

-IA-

"1 5 Technical Field This invention is directed to temperature stable semisynthetic cephalosporin salts whose preparation has not been described in the literatuie, to the preparation of such salts, and to admixtures containing these salts.

Background Of The Invention Aburaki et al. U.S. Patent No. 4,406,899 discloses 7- (2-aminothiazol-4-yl) -methoximinoacetamido] -3- S(l-methyl-1-pyrrolidinio)-methyl]-3-cephem-4-carboxylate in the zwitterion form and mentions corresponding acid addition salts (which are present in the zwitterion form in injectable compositions) and shows that the zwitterion form has broader spectrum activity than ceftazidime and cefotaxime.

However, the aforementioned Aburaki et al. cephalosporins are stable only for a few hours as injectable compositions and the zwitterion form even as a dry powder is unstable at room temperature and loses 30% or more of its activity on storage at elevated temperatures 45 deg. C and above) for even one week and therefore requires special insulated packaging and/or refrigeration and is at a packaging and storage disadvantage compared to ceftazidime and cefotaxime.

While Aburaki et al. mentions acid addition salts, the patent does not state how to make these or state which if any of these salts have good stability in dry powder form. /Kessler et al., "Comparison of a New Cephalosporin, BMY 28142, with Other Broad-Spectrum ,-Lactam Antibiotics", Antimicrobial Agents and S.Chemotherapy, Vol. 27, No. 2, pp. 207-216, February 1985 mentions the sulfate salt, but does not disclose how to prepare such or that this salt has room temperature stability and good elevated temperature stability in dry powder form.

-2- Summary Of The Invention It has been discovered herein that certain crystalline acid addition salts of 7-[a-(2-aminothiazol-4-yl)-a-(Z)methoxylminoacetanldo)-3-l (1-methyl-l-pyrrolidinio)-methyl]- 3-cephem-4-carboxylate in dry powder form have excellent room temperature stability and have superior elevated temperature stability compared to the zwitterion form. The term "dry powder form" as used herein means a moisture content of less than 5% by weight.

|0 These acid addition salts are the crystalline salts of (2-aminothiazol-4-yl)-a-(Z)-methoxyiminoacetamido -3- (-methyl-l-pyrrolidinio) -methyl] -3-cephem-4-carboxylate selected from the group consisting of the sulfuric, di-nitric, mono-hydrochloric, and di-hydrochloric acid addition salts and orthophosphoric acid addition salts (1.5-2 moles of .',orthophosphoric acid per mole of salt, e.g. a range of from the sesqui- to the di-orthophosphoric acid salts), or solvates thereof. The term "crystalline" is used herein to mean at least Ssome characterizing arrangement of molecules. While the 4 a sulfuric, di-nitric, di-hydrochloric and orthophosphoric acid addition salts herein are prepared in clearly crystalline form S (as evidenced by birefringence under a polarizing microscope) with precise arrangement of molecules, the mono-hydrochloric acid addition salt has been prepared only with some regularity in the arrangement of its molecules (as evidenced by poor birefringence 'under polarizing microscope) and not a precise predictable arrangement and thus is "poorly" crystalline. The term "crystalline" is used herein to embrace not only the clearly crystalline salts but also the "poorly" appearing crystalline mono-hydrochloric acid addition salt.

The acid addition salts herein when formed into aqueous injectable compositions provide the zwitterion in solution. The zwitterion has the structure ,_s 7 The broad spectrum utility against various organisms of the zwitterion form, and thus of aqueous compositions made up from the salts herein, iF shown by the data in Aburaki et al. U.S.

4,406,899.

Aqueous compositions made up from the acid addition salts herein simply by the addition of sterile water provide acidic solutions which provoke unacceptable irritation on intravenous administration to rabbits and unacceptably painful sensation on intramuscular administration to rabbits. The sulfuric acid and 10 di-ritric acid addition salts have reduced solubilities which are insufficient for typical injectable compositions. It has been fonnd herein that these objectionable characteristics are overcome by utilizing the salts herein in physical admixture (that is as an admixture of solids) with a pharmaceutically acceptable non-toxic organic or inorganic base in proportions to provide a pH of about 3.5 to about 7 on dilution with water to a '::zwitterion activity of from 1 mg/mi to 400 mg/m.1, normally 250 'Kmg/mi. (as determined by high pevfformance liquid chromatography, ,hereinafter HPLC).

I

a A preferred salt herein is the crystalline sulfuric acid addition salt. It is preferred because its low solubility in water (25 mg/mi) allows high recovery from aqueous medium on crystallization.

The crystalline sulfuric acid addition salt is readily "'prepared by a process comprising the steps of forming an OA, 0 w (admixture of at least 1 molar equivalent of sulfuric acid and (ii) zwitterion in an amount so as to be present in the admixture at a concentration greater'than 25 mg/ml, 11b) causing crystallization of the sulfuric acid addition salt to occur, and isolating crystalline sulfuric acid addition salt.

-4- Detailed Description The crystallije salts herein (hereinafter referred to simply as the salts herein) have excellent stability at room temperature and have a potency loss (as determined by HPLC), of less than I% on storage for a month at room temperature. These salts also have excellent stability at elevated temperatures and have a potency loss (as determined by HPLC) of less than 15% on storage for a month at 45-56 deg. C.

The sulfuric acid addition salt is a preferred salt herein.

It has a potency loss of less than 10% on storage for a month a 45-56 deg. C. Very importantly, it has a low solubility in water, i.e. about 25 mg/ml, and therefore is crystallized from water with minimized residual loss.

The di-nitric acid addition salt herein also has a low solubility in water, i.e. about 60 rng/ml, and therefore also provides low residual loss on crystallization from water.

The mono-hydrochloric, di-hydrochloric and sesqui- or di-orthophosphoric acid addition salts have water solubilities greater than 200 mg/ml., and therefore are preferably crystallized 20-0 from organic solvents, rather than frcm water, in order to obtain 00000good yields.

We turn now to the preparation of the salts herein.

As previously indicated the sulfuric acid addition salt herein is prepared by a process comprising the steps of (a) 25 forming an(admixture of at least one molar equivalent of sulfuric acid and (ii) zwitterion corresponding to said salt in an amount so as to be present in the admixture at a concentration of greater than 25 mg/ml, causing crystallization to occur, and isolating crystalline sulfuric acid addition salt.

lil---Y ^_l Preferably the zwitterion is used in step in an amount so as to be present in the admixture at a concentration ranging from about 100 ag/ml to about 200 mg/ml, and step is carried out in an aqueous medium free of organic solvent. Normally no more than 2 molar equivalents of sulfuric acid are utilized in step Normally zwitterion is used in step in an amount so as to be present in the admixture at a concentration less than 500 mg/ml.

Step is readily carried out either by adding solid zwitterion to sulfuric acid solution IN H2SO 4 with rapid stirring to form a solution. Alternatively step can be carried by dissolving solid zwitterion in water and slowly adding sulfuric acid with stirring to form a solution.

Step is carried out by inducing crystallization, preferably by seeding, and then slurrying, preferably for minutes to 2 hours. It is preferred that this crystallization step be carried out in aqueous medium, free of organic solvent, and in such case purities greater than 98% are normally obtained.

While the presence of organic solvent, such as acetone, fosters crystallization and increases yield by lowering the solubility of the formed sulfuric acid addition salt in the crystallization medium, it also can foster precipitation of impurities resulting in decreased purity. When the zwitterion is used in step in an amount so as to be present in the admixture in an amount less than 25 mg/ml, organic solvent, preferably acetone, must be included in the crystallization medium to provide reasonable recovery. When acetone is used, it is appropriately used in amounts of 0.5 to 10 volumes per volume of aqueous crystallization medium. 9 Step is carried out by separating the crystals from the crystallization medium, preferably by vacuum filtration, then washing e.g. with acetone/water followed by acetone alone or 0.1N sulfuric acid 1/10 volume) followed by acetone 1/4 -6- -1 volume), and then drying, e.g. by vacuum drying at 30-50 deg. C for 4-20 hours.

The method herein for forming the sulfuric acid addition salt results in the purification of the zwitterion form because of the limited solubility of the sulfuric acid addition salt compared to the zwitterion form and can be used to purify iwitterion without isolating it as a solid. If it is desired to obtain substantially pure zwitterion (free-base) from the formed sulfuric acid addition salt, this can be carried out by dissolving the salt in water, adding Ba(OH) 2 .8H 2 0 in an amount of 90-100% of theory at a pH of less than 6.5 to precipitate BaSO 4 filtering to remove the BaSO 4 and recovering the filtrate containing the zwitterion dissolved therein and utilizing it as a solution or isolating solid zwitterion (free-base) by lyophilizing it or by adding acetone to precipitate amorphous zwitterion followed by isolating solid zwitterion by vacuum filtration, washing e.g. with acetone, and vacuum drying.

Alternatively, the sulfuric acid addition salt is converted to the free-base utilizing ion exchange resins, e.g. Dowex WGR (a 2

V

weak base anion exchange resin) and Dowex XU-40090.01 (a strong acid cation exchange resin) with subsequent lyophilization.

Turning now to the preparation of the crystalline di-nitric acid addition salt herein, this is obtained by admixing at least two molar equivalents of nitric acid and (ii) zwitterion corresponding to said salt so to be present in the admixture at a S concentration greater than 100 mg/ml, and then inducing crystallization by seeding or rubbing with a glass rod, diluting with 2-propanol and cooling. The crystalline di-nitric acid addition salt is recovered e.g. by filtering, washing sequentially, e.g. with 2-propanol-H 2 0 (50% 2-propanol, and ether, and then vacuum drying at 50 deg. C for 2 hours.

The mono-hydrochloric acid addition salt herein is prepared by dissolving zwitterion in approximately one molar equivalent of -7- I hydrochloric acid and causing crystallization by adding acetone with stirring and continuing to stir, followed by isolating crystals, e.g. by vacuum filtration followed by washing with acetone and vacuum drying. Alternatively the mono-hydrochloric acid addition salt is formed from the di-hydrochloric acid addition salt by slurrying the di-hydrochloric acid addition salt in methylene chloride and adding 1 mole equivalent of triethylamine followed by slurrying to form the mono-hydrochloric acid addition salt which is isolated, e.g. by vacuum filtration, followed by washing with methylene chloride and vacuum drying.

The crystalline di-hydrochloric acid addition salt herein is prepared by dissolving zwitterion in at least two molar equivalents of hydrochloric acid, then causing crystallization by adding acetone, then isolating crystals e.g. by vacuum filtration, washing with acetone and vacuum drying.

The crystalline di-orthophosphoric acid addition salt herein is prepared by dissolving the zwitterion in at least 2 molar equivalents of phosphoric acid, cauzing crystallization by adding acetone, and isolating crystals by e.g. by vacuum filtration a 4 followed by washing first with acetone and then with ether and then vacuum drying. The crystalline sesqui-orthophosphoric acid S. addition salt is formed by this same procedure except that about molar equivalents of phosphoric acid is used.

The salts herein are formed into injectable compositions by diluting with sterile water and buffering to a pH of 3.5-7 to form an injectable concentration of 1 mg/ml up to 400 mg/ml of zwitterion. Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, lysine and arginine. For intramuscular or intravenous administration to an adult human, a total dosage of from about 750 to about 3000 mg per day in divided doses is normally sufficient.

The salts herein are not desirably formed into injectable compositions simply by the addition of sterile water because the sulfuric and di-nitric acid addition salts are not sufficiently soluble to fo-rm compositions of normal concentration for admninistration and because the salts herein when dissolved provide very low pH compositions which provide painful sensation on injection. As indicated above, it has been found herein that these shortcomings are overcome by forming the salts herein into a physical, i.e. solid, adm~ixture with pharmaceutically acceptable, normally solid non-toxic organic or inorganic bases in proportions to provide a pH ranging from about 3.5 to about 7, preferably from about 4 to about 6, on dilution of the admixture with water to injectable concentration of I mg/mi up to 400 mg/mi of zwitterion, e.g. zwitterion activity of 250 mg/mi as determined by HPLC assay.

The exact proportions of ingredients in the physical admixture vary from lot to lot of the salt since the purity of the salt varies from ict to lot.' The proportions of ingredients are established for a particular lot by pretitrating in respect to a samnple to obtain a selected pH within the aforementioned range.

The physical admixture is readily stored and shipped in solid form thereby taking advantage of the stability of the salts herein and is readily converted into an injectable composition simply by addition of water, e.g. by a nurse or doctor, just prior to use.

The physical admixture is prepared by blending the salt and the base into a uniform blend, e.g. utilizing a standard blender in a dry atmosphere, and is then preferably filled into a vial or other container, all under aseptic conditions.

The bases for use in the admixture include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamiie, L(4y lysine and arginine. lysine -9- -I i and arginine are preferred since admixtures containing these are reconstituted to provide injectable compositions which on injection provide less pain in animals than compositions derived from admixtures containing other bases. The lysine is very preferably utilized in a proportion to provide a pH of 3.5-6 on dilution of the admixture with water to provide a composition with a zwitterion activity of 250 mg/ml (as determined by HPLC assay).

The salts herein and substantially dry physical admixtures containing them can be stored without refrigeration or insulated packaging and still retain high potency.

In several of the preparations herein the unstable zwitterion is used as the starting material. The preparation of this is described in Examples 1-3 of Aburaki et al. U.S.

4,406,899. The zwitterion is referred to in Aburaki et al. as S7-[(Z)-2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido-3-[(1nmethyl-l-pyrrolidinium)methyl]-3-cephem-4-carboxylate.

The invention is illustrated in the following working examples.

Example

I

e at Preparation of the Sulfuric Acid Addition Salt g of zwitterion are added slowly to 10 ml of rapidly stirred IN H 2

SO

4 (1.59 molar equivalents) at 20-26 deg. C. A solution is obtained. Crystallization is then induced by seeding with crystalline sulfuric acid addition salt and the crystalline mass is slurried for 0.5 hours. The crystals are then separated by vacuum filtration, washed with 3 ml of 50% acetone/water (V/V) and with two 5 ml portions of acetone, and vacuum dried at 40-50 deg. C overnight.

A typical yield Is 1.3 g of sulfuric acid addition salt.

Analysis: Calculated for C 19

H

2 4

N

6 0 5

S

2

.H

2 S0 4 3 .44; IH, 4.53; 14.52; IS, 16.621 %H 2 0, none. Found: 38.91; %H, 14.64; iS, 16.71; %H20, 1.42.

Example 11 Preparation of the Sulfuric Acid Addition Salt g of zwitterion are dissolved in 5 ml of Water. 5 ml of IM H 2 So 4 are slowly added to this solution with stirrinq.

Crystallization is then induced by seeding with crystalline acid addition salt and the crystalline mass is slurried for 0.5 hours.

The crystals are then separated by vacuum filtration, washed with 3 ml of 50% acetone/water and with two 5 ml portions of acetone, and vacuum dried at 40-50 deg. C overnight.

A typical yield is 1.3 g of sulfuric acid addition salt.

oExample

III

Preparation of the (HNOz), Acid Addition Salt 300 mg of zwitterion are dissolved in 2N nitric acid ml). The solution is rubbed with a glass rod, diluted with 2-propanol (0.4 ml) and cooled. The crystalline title compound is collected and is sequentially washed with 0.4 ml of 2-propanol

H

2 0 2-propanol and then ether to afford 127 mgs of the dinitrate salt.

Analysis: Calculated for C 19H 24N605S2HO3 37.62; 4.32; 18.47; 10.57. Found: 36.92; 4.10; 18.08; 10.67; (H 2 0 content 0.90%).

-11- Example IV Preparation of the Monohydrochloride Acid Addition Salt 1 g of zwitterion is dissolved in 2.08 ml of IN HCl (1 molar equivalent) at 20-25 deg. C. Thirty ml of acetone are added with rapid stirring over a 15 minute period whereby crystals form.

Stirring is continued for 1 hour. The crystals are isolated by vacuum filtration, washed with 10 ml of acetone and vacuum dried at 50 deg. C for 2 hours.

A typical yield is 0.9 g of crystalline monohydrochloride salt. Analysis: Calculated for C 19

H

24

N

6 0 5

S

2 .HCl: 41.37; 4.75; 15.2; 11.63; %Cl, 12.86. Found: 39.32; 4.88; 13.95; 11.28; %Cl, 12.44; %H 2 0, (Corrected for H 20: 41.17; 14.61; 11.82; %C1, 13.03).

Example V Preparation of the Dihydrochloride Acid Addition Salt and Preparation of the Monohydrochloride Acid Addition Salt From It 350 mg of zwitterion are dissolved in 2 ml of IN-HCI. 10 ml of acetone are added to the resultant solution, with rapid stirring 2b and over a 5 minute interval, whereby crystals form. Stirrinq is continued for 5 additional minutes. Then 10 additional ml of i acetone are added and stirring is carried out for 0.5 hours. The crystals are removed by vacuum filtration, washed with two 5 ml i 25 portions of acetone and vacuum dried at 40-45 deg. C for 24 hours.

A typical yield is 300 mg of crystalline dihydrochloride acid addition salt. Analysis Calculated for -12-

C

1 9

H

2 4

N

6 0 S 2 .2HC1: 41.38; 4.75; tN, 15.2; 11.62; %Cl, 12.8. Found: 40.78; 4.98; 14.7; tS, 11.25; 1.25. (Corrected for H20: 41.1; 14.88; iS, 11.39; Cel, 11.94).

1 g of dihydrochloride salt prepared as above is slurried in ml of methylene chloride at 20-25 deg. C in a sealed flask and 0.28 ml of triethylamine is added over a 15 minute interval. The crystalline mass is then slurried for 5 hours. The resultant mohohydrochloride crystals are then isolated by vacuum filtration, washed with two 5 ml portions of methylene chloride and vacuum dried at 50 deg. C for 2 hours. A typical yield is 800 mg.

Example VI Preparation of the Di-orthophosphoric 1s ,Acid Addition Salt 1 g of zwitterion is dissolved in 3.4 ml of 144 mg/ml

H

3

PO

4 (2.2 molar equivalents) at 15 deg. C. The resulting solution is suitably filtered to clarify it. 12 ml of acetone are added to the clarified solution, with raoid stirrino and over a 10 minute period,whereby crystals form. Stirring is continued for 10 minutes. Then 30 ml of acetone are added over a 10 minute period, and stirring is continued for an additional 15 minutes.

The crystals are collected by vacuum filtration, washed with two ml portions of acetone and two 5 ml portions of ether anc dried under high vacuum for 16 hours.

A typical yield for this type of preparation was 1.1 g of crystalline di-orthophosphoric acid addition salt. Analysis: -j Calculated for C 1 9 i 2 4

N

6 0 5

S

2 .2H 3

PO

4 t C, 33.721 4.47; 12.42. Foundt 33.431 4, 4.65; tN, 12.02; IH20, 1.82.

(Corrected for H120 34.01 IN, 12.2).

-13- 6h.. The sesqui-orthophosphoric acid addition salt is formed as above except that 1.5 molar equivalents of H 3

PO

4 are used instead of 2.2 molar equivalents.

Example VII Stabilities at Elevated Temperatures Elevated temperature stabilities were determined by storing the preparations in dry containers at temperatures and for time periods as denoted below and potency losses or gains were determined by HPLC. A potency gain is indicated by a plus sign in front of a figure. A less than 10% potency loss over a 2 to 4 week period at 45-56 deg. C is usually indicative of less than potency loss over a 2-3 year period at roso temperature.

J-14- -14- 7 PERCENT LOSS Deg. C 56 Deg. C 300 Deo.( (Weeks) MLeeks) (Days) Form 1 2 4 6 1Lj 2 4 1 Zwitterion 37 51 71 57 300 H 2 so 4 Salt 2.4 to 45 3 +5 1.4 5 to 46 43 0 to +6 0-20 (JNO 3)2 Salt 8.8 3.4 0.68 10.3 3.7 2.4 HCI Salt 4.8 2 6.0 6.4 6.~4 1t2~~~16.

(HCl) 2 Salt (jH PO4) Salt 0 7.4 7.2 12.4 0 I 3.0 11.0 1 2.7 I J Example VIII Testing of Physical Admixtures Physical admixtures were made up of crystalline sulfuric acid salt with txisodium orthcophosphate, sodium bicarbonate, lysine, and arginine. The bases were added in proportions to provide pH's on dilution of the admixture with water to a zwitterion activity of 250 mg/mi (as determined by HPLC assay) as follows: trisodium orthophosphate (to provide a pH of sodium bicarbonate (to provide a pH- of lysine (to provide a pH o~f arginine (to provide a pH of Injectable compositions were made up by reconstituting with sterile water to a twitterion activity of 250 mg/ml as determined by HPLC assay. There were no solubility problems. Injections (100 mg/kg) were carried out intramuscularly on rabbits with pain within acceptable thresholds. The least pain wi. with the arginine containing comp sition.

Similar results of good solubility and acceptable pain on intramuscular injection are obtained on use of the other salts herein in the physical admixtures with the above bases.

Figure 1 is the infra red absorption spectrum of the crystalline sulfate salt prepared as described in Examples I or SII pelletized in the crystalline form with potassium bromide.

The X-ray powder diffraction pattern of the crystalline sulfate salt of 7-[a-(2-aminothiazol-4-yl)-a-(z)-methoxyiminoacetamido] (l-methyl-l-pyrrolidinio) -methyl] -3-cephem-4carboxylate prepared as described in Example I or II was determined with a Rigaku Powder Diffractometer using a copper target X-ray tube, a nickel filter, and the sample contained in a glass dish. The scan rate was 2 deg./min. over the range from deg. to 40 deg. and a chart was mechanically recorded to show the angles of maximum diffraction. Frcm this the spacings and S relative intensities (1/10) were calculated. They are listed below.

I-

3S -16- .4 0 d spacing (A) 9.20 6.80 5.50 5.09 4.50 4.41 4. 19 3.78 3.64 3.39 3.31 3.15 1/10 (t) 100 28 22 38B 44 63 38 44 31 47 4 -17i PREPARATION OF THE SESQUIPHOSPHATE SALT The zwitterion, 0.70 is dissolved with rapid stirring in from 2.2 to 2.4 ml. of 85% phosphoric acid (2.1 to 2.2 molar equivalents) which has been diluted 1:10 (v/v) with water. The solution is clarified by filtration through a 0.22-0.45 micron pore-size membrane filter. From 5 to 7 parts by volume (15-20 ml) of methanol is added to the filtrate with rapid stirring during a 30 to 60 min. period.

Crystals form during this operation, and rapid stirring is continued for 1.5 to 2 hours. The crystalline product is recovered by vacuum filtration. The product is washed on the filter first with 6 to 8 ml of 1:1 (v/v) methanol:acetone taking care to maintain a tightly packed o filter cake, and then with acetone. The product is dried in vacuo at 50° C for 2 hours; typical yield 0.7 to 0.75 g.

Infrared Interpretation (See Figure 2) (IR, KBr pellet) -1 Peak Position (cm Functional Group 2800-3400 NH,NH 3 ,carboxyl OH 1780 3-lactam C=O 1680 Carboxyl C=O S1660 Amide C=O 1630

C=N,C=C

1550 Amide OH 980,1040 PO 4 18 Behavior On Heating An exotherm is shown calorimeter tracing.

X-Ray Diffraction Pattern at 171.8°C in the differential scanning The X-ray powder diffraction pattern of the foregoing sesquiphosphate salt was measured with a Rigaku Powder Diffractometer in the same fashion as described above with respect to sulfate salt with the following results.

11.04 9.2 7.89 7.02 6.7 4.64 4.456 4.3 3.88 3.75 3.56 3.31 3.05

I/I"

32 16 24 42 32 26 300 53 58 26 89 21 26 6 :li: 1

J

19 2- 4 NTR Interpretation H 90 MHz NMR, D 2 0 solution) 26o 1 Chemical Shift (ppm 5 vs. TSP) 2.0-2.4 3.04 3.3-3.6 3.94 4.12 4.12 4.8 5.42 5.88 7.21 Description Multiplet Singlet.

Multiplet Doublet Singlet.

Doublet Doublet Doublet Doublet Singlet Integral 4 3 5 1 .3 Assignment 14CH 2 14'CH 2 12CHR 3 2CR, 13CH 2 13'CH 2 2CR 20CH 3 11CR 11CR 6CR 7CR 18CR j 20 Vi Stability Time-Temperature day; 10011C days; 7 0

'C

days; 70*C week 56 0

C

weeks; 56'C weeks; 56 0

C

week; 45 0

C

weeks; 45'C weeks; '15*C weeks; 45 0

C

month; 37 0

C

Loss 10.9 0 1.9 1.4 0 0 1-4 0.7 1-6 Elemental Analysis (percent by weight) Found 35.44 4.66 12.88 2. 29* 23.06 Dry Basis 36.3 4.41 13.2 Theory (Sesquiphosphate) 36.4 4.7 13. 4 monohydrate H 2 0 23.6 HO2 2

P

23.6 *Karl Fischer Method exy 21

Claims

1. Temperature stable crystalline salts of aminothiazol-4-yl)--(Z)-methoxyiminoacetamido]-3-[(1-methyl-l- pyrrolidinio)-methyll-3-cephem-4-carboxylate selected from the group consisting of the sulfuric, di-nitric, mono-hydrochloric, and di-hydrochloric acid addition salts, and orthophosphoric acid addition salts containing 1.5-2 molar equivalents of H 3 P0 4 -e V slvto threof.

2. The crystalline salts of Claim 1 selected from the group consisting of the sulfuric, mono-hydrochloric, di-hydrochloric I and orthophosphoric acid addition salts.- th-rof.n

3. A physical admixture of the salt of Claim 1 with a pharmaceutically acceptable non-toxic organic or inorganic base in proportions to provide a pH of about 3.5 to about 7 on dilution of the admixture with water to injectable concentration.

4. A physical admixture as recited in Claim 3 wherein the salt and the base are present in proportions to provide a pH of about 4 to about 6 on dilution of the admixture with water to S injectable concentration.

5. A physical admixture as recited in Claim 4 wherein the base is lysine.

6. A physcial admixture as recited in Claim 4 wherein the base is arginine. -22- -j

7. A method for making the sulfuric acid addition salt comprising the steps of forming an aqueous admixture of at least 1 molar equivalent of sulfuric acid and (ii) zwitterion corresponding to said salt. causing crystallization of the sulfuric acid addition salt to occur, provided that when the zwitterion is present in the admixture at a concentration of less than 25 mg/ml the crystallization is carried out in the presence of an organic Solvent, and isolating crystalline sulfuric acid addition salt.

8. Method as recited in Claim 7 where step is carried out in an aqueous medium free of organic solvent.

9. The method as recited in Claim 8 wherein the zwitterion is used in Step in an amount so as to be present in the admixture at a concentration less than 500 mg/ml.

The method as recited in Claim 7 wherein the amount of zwitterion employed in Step is such that it is present in the admixture at a concentration greater than 25 mg/ml. /dX -23-

11. The -method as recited in Claim 8 wherein the zwitterion -is used in Step in an amount so as to be present in the admixture at a concentration ranging frim about 100 mg/mi to about 200 mg/mi.

12. The crystalline sulfuric acid addition salt of Claim I.

13. Crystalline 7-[a-(2-afinothiazol4yl)-a(Z-methoxy- 4lnoacetamido)-3[ (methyl-lpyrrolidinio) kmethyl>-3cephem- 4 zazboxylate sulfate salt havin-. the following X-ray powder diffraction pattern: d spacing 9.20 6. 86 5.50 5.09 4.50 4. 41 4.19 3.78 3.64 3.39 3.31 3.15 0 I/I M% 100 28 22 38 44 63 38 44 31 47 -24- r

14. The crystalline orthophosphoric acid addition salt of Claim 1, and hydrates thereof.

Crystalline 7-[a-(2-aminothiazol-4-yl)-a-(Z)- methoxyiminoacetamido]-3-[ (-methylpyrrolidinio)- methyl]-3-cephem-4-carboxylate phosphate having the following X-ray powder diffraction pattern. d I/I1 11.04 32 9.2

16 -I 7.89 24 7.02 42 6.7 32 26 4.64 100 4.456 53 4.3 58 3.88 26 3.75 89 3.56 21 3.31 26 3.05 16 S 16. A temperature stable crystalline salt as claimed in claim 1, substantially hereinbefore described with reference to any one of the examples.

17. A method as claimed in claim 7, substantially hereinbefore described with reference to any one of the 3, examples, DATED: 15th July, 1986 PHILLIPS ORMONDE FITZPATRICK~I S f Attorneys for: .BR-I-S.TOLMY-ERS -GOMP AN2Y I r r